Could social prescribing contribute to type 2 diabetes prevention in people at high risk? Protocol for a realist, multilevel, mixed methods review and evaluation.
Could social prescribing contribute to type 2 diabetes prevention in people at high risk? Protocol for a realist, multilevel, mixed methods review and evaluation.
复制标题
DOI：
10.1136/bmjopen-2020-042303
复制
发表时间：
2021-04-09
期刊：
影响因子：
2.9
通讯作者：
Finer S
中科院分区：
文献类型：
--
作者：
Calderón Larrañaga S;Clinch M;Greenhalgh T;Finer S
社会处方是英国国家卫生服务政策中广泛采用的一项创新，作为改善2型糖尿病（T2 D）等长期疾病患者管理的一种方式。它通常涉及将初级保健中的病人与非医疗社区干预措施联系起来。尽管得到了广泛的国家支持，但社会处方的有效性的证据既不充分，也有争议。在这项研究中，我们将调查社会处方是否有助于T2 D预防，如果是这样，何时，如何以及在什么情况下最好引入。我们将借鉴现实主义的评估，调查复杂的人际，组织，社会和政策背景下，社会处方相关的T2 D预防实施。我们将成立一个利益相关者小组，在整个研究过程中向我们提供意见。在第一阶段，我们将进行一项现实主义的审查，以综合目前的证据基础，为社会处方。在第二阶段，我们将调查如何社会处方相关的人在高风险的T2 D“作品”在一个多民族，社会经济多样化的社区和任何互动与现有的T2 D预防服务使用定性，定量和现实主义的方法。在第3阶段和前几个阶段的基础上，我们将综合一个“可转移的框架”，以指导实施和评估与T2 D预防相关的社会处方。国家卫生局的道德标准已得到批准（参考20/LO/0713）。该项目可能会为社会处方服务的调整提供信息，以更好地满足社会经济贫困地区T2 D高风险人群的需求。研究结果也可以转移到其他长期条件。传播工作将在利益攸关方团体的支持下，作为一个持续的进程进行。量身定制的产出将针对以下受众：（1）服务提供者和专员;（2）2型糖尿病高危人群和社区利益攸关方;（3）政策和战略决策者。CRD 42020196259。
Social prescribing is an innovation being widely adopted within the UK National Health Service policy as a way of improving the management of people with long-term conditions, such as type 2 diabetes (T2D). It generally involves linking patients in primary care with non-medical community-based interventions. Despite widespread national support, evidence for the effectiveness of social prescribing is both insufficient and contested. In this study, we will investigate whether social prescribing can contribute to T2D prevention and, if so, when, how and in what circumstances it might best be introduced. We will draw on realist evaluation to investigate the complex interpersonal, organisational, social and policy contexts in which social prescribing relevant to T2D prevention is implemented. We will set up a stakeholder group to advise us throughout the study, which will be conducted over three interconnected stages. In stage 1, we will undertake a realist review to synthesise the current evidence base for social prescribing. In stage 2, we will investigate how social prescribing relevant to people at high risk of T2D ‘works’ in a multiethnic, socioeconomically diverse community and any interactions with existing T2D prevention services using qualitative, quantitative and realist methods. In stage 3 and building on previous stages, we will synthesise a ‘transferable framework’ that will guide implementation and evaluation of social prescribing relevant to T2D prevention at scale. National Health Service ethics approval has been granted (reference 20/LO/0713). This project will potentially inform the adaptation of social prescribing services to better meet the needs of people at high risk of T2D in socioeconomically deprived areas. Findings may also be transferable to other long-term conditions. Dissemination will be undertaken as a continuous process, supported by the stakeholder group. Tailored outputs will target the following audiences: (1) service providers and commissioners; (2) people at high risk of T2D and community stakeholders; and (3) policy and strategic decision makers. CRD42020196259.
登录
查看更多内容
影响因子：
5.1
作者：
Davies, Melanie J.;Gray, Laura J.;Yates, Thomas
通讯作者：
Yates, Thomas
制定和评估复杂的干预措施：新的医学研究委员会指南。
DOI：
10.1136/bmj.a1655
发表时间：
2008-09-29
期刊：
BMJ (Clinical research ed.)
影响因子：
--
作者：
Craig P;Dieppe P;Macintyre S;Michie S;Nazareth I;Petticrew M;Medical Research Council Guidance
通讯作者：
Medical Research Council Guidance
影响因子：
9.3
作者：
Barry E;Greenhalgh T;Fahy N
通讯作者：
Fahy N
影响因子：
3.4
作者：
Fetters, Michael D.;Curry, Leslie A.;Creswell, John W.
通讯作者：
Creswell, John W.
影响因子：
3.5
作者：
Dreyer, G.;Hull, S.;Yaqoob, M. M.
通讯作者：
Yaqoob, M. M.